

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS	3	AUG 06	FSTA enhanced with new thesaurus edition
NEWS	4	AUG 13	CA/Capplus enhanced with additional kind codes for granted patents
NEWS	5	AUG 20	CA/Capplus enhanced with CAS indexing in pre-1907 records
NEWS	6	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS	7	AUG 27	USPATOLD now available on STN
NEWS	8	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS	9	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS	10	SEP 13	FORIS renamed to SOFIS
NEWS	11	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS	12	SEP 17	CA/Capplus enhanced with printed CA page images from 1967-1998
NEWS	13	SEP 17	Capplus coverage extended to include traditional medicine patents
NEWS	14	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	15	OCT 02	CA/Capplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS	16	OCT 19	BEILSTEIN updated with new compounds
NEWS	17	NOV 15	Derwent Indian patent publication number format enhanced
NEWS	18	NOV 19	WPIX enhanced with XML display format
NEWS	19	NOV 30	ICSD reloaded with enhancements
NEWS	20	DEC 04	LINPADOCDB now available on STN
NEWS	21	DEC 14	BEILSTEIN pricing structure to change
NEWS	22	DEC 17	USPATOLD added to additional database clusters
NEWS	23	DEC 17	IMSDRUGCONF removed from database clusters and STN
NEWS	24	DEC 17	DGENE now includes more than 10 million sequences
NEWS	25	DEC 17	TOXCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment
NEWS	26	DEC 17	MEDLINE and LMEDLINE updated with 2008 MeSH vocabulary
NEWS	27	DEC 17	CA/Capplus enhanced with new custom IPC display formats
NEWS	28	DEC 17	STN Viewer enhanced with full-text patent content from USPATOLD
NEWS	29	JAN 02	STN pricing information for 2008 now available
NEWS	30	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS	31	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS	32	JAN 28	MARPAT searching enhanced
NEWS	33	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS	34	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS	35	JAN 28	MEDLINE and LMEDLINE reloaded with enhancements

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2,

CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 18:24:28 ON 30 JAN 2008

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 18:24:38 ON 30 JAN 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 29 JAN 2008 HIGHEST RN 1001040-86-3

DICTIONARY FILE UPDATES: 29 JAN 2008 HIGHEST RN 1001040-86-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10552493.str



ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14

chain bonds :


6-10
ring bonds :
1-5 1-2 2-3 3-4 4-5 4-6 5-9 6-7 7-8 8-9 10-11 10-14 11-12 12-13 13-14

exact/norm bonds :
1-5 1-2 6-10 10-11 10-14 11-12
exact bonds :
2-3 3-4 12-13 13-14
normalized bonds :
4-5 4-6 5-9 6-7 7-8 8-9
isolated ring systems :
containing 1 : 10 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 18:25:09 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 21 TO ITERATE

100.0% PROCESSED 21 ITERATIONS 4 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 146 TO 694
PROJECTED ANSWERS: 4 TO 200

L2 4 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 18:25:13 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 338 TO ITERATE

100.0% PROCESSED 338 ITERATIONS 86 ANSWERS
SEARCH TIME: 00.00.01

L3 86 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
178.36	178.57

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 18:25:17 ON 30 JAN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 30 Jan 2008 VOL 148 ISS 5
FILE LAST UPDATED: 29 Jan 2008 (20080129/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 13 full

L4 5 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:1093832 CAPLUS
DOCUMENT NUMBER: 145:438607
TITLE: Process for preparing heterocyclylpyrrolopyridines and

their use as antagonists of corticotropin-releasing factor (CRF) receptors.
INVENTOR(S): Andreotti, Daniele; Bacchi, Sergio; Delpogetto, Monica; Gueffi, Simone; Perboni, Alcide; Ribecai, Arianna; Spada, Simone; Stabile, Paolo; Tampieri, Marsia

PATENT ASSIGNEE(S): SB Pharmco Puerto Rico Inc, USA; Neurocrine

Source: Biosciences Inc

PCT Int. Appl., 42pp.

CODEN: PIXXD2

Patent

English

FAMILY ACC. NUM. COUNT: 1



PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006108689	A2	20061019	WO 2006-EP3480	20060406
WO 2006108689	A3	20070201		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
AU 2006233736	A1	20061019	AU 2006-233736	20060406
CA 2604397	A1	20061019	CA 2006-2604397	20060406
EP 1869039	A2	20071226	EP 2006-724355	20060406
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, GB 2005-7195			A 20050408
PRIORITY APPLN. INFO.:			WO 2006-EP3480	W 20060406

OTHER SOURCE(S):


MARPAT 145:438607

GI




L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN

(Continued)



RN 491864-40-5 CAPLUS
CN Benzonitrile,
4-[2,3-dihydro-6-methyl-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]-1H-pyrrolo[2,3-b]pyridin-1-yl]-3-methyl- (CA INDEX NAME)



RN 491864-41-6 CAPLUS
CN Benzonitrile,
4-[2,3-dihydro-6-methyl-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]-1H-pyrrolo[2,3-b]pyridin-1-yl]-3-(trifluoromethyl)- (CA INDEX NAME)

L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

AB A process for preparation of title compds. [I; R = (substituted) aryl, heteroaryl; R1 = H, alkyl, alkenyl, alkynyl, haloalkyl, haloalkoxy, halo, amino, cyano; R2 = H, cycloalkyl, R9; R3 = cycloalkyl, R9; R9 = (substituted) alkyl; R2RIN = (substituted) 5-14 membered heterocycle] comprises treatment of (III; X = halo; R, R1 as above) with a Cu catalyst and a reactive derivative of the residue NR2R3. Thus, CuI and trans-N,N'-1,2-diaminocyclohexane were stirred together for 2-12 h in NMP;

K2CO3, 2-(1H-pyrazol-3-yl)thiazole (preparation given), and

3-iodo-6-methyl-1-[2-methyl-4-(methoxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine (preparation given) in NMP were added followed by heating at 125° for 12-18 h to give 70% 6-methyl-1-[2-methyl-4-(methoxy)phenyl]-4-[3-(thiazol-2-yl)-1H-pyrazol-1-yl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine.

IT 912848-66-9P


RL: IMP (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heterocyclylpyrrolopyridines and their use as antagonists of

corticotropin-releasing factor (CRF) receptors)

RN 912848-66-9 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine, 2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-4-[5-(2-thiazolyl)-1H-pyrazol-1-yl]- (CA INDEX NAME)



IT 491864-38-1P 491864-40-5P 491864-41-6P

491864-42-7P 491864-46-1P 491865-57-7P

491865-58-8P 491865-59-9P

RL: IMP (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(preparation of heterocyclylpyrrolopyridines and their use as antagonists of

corticotropin-releasing factor (CRF) receptors)


RN 491864-38-1 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine,


1-[2,4-bis(trifluoromethyl)phenyl]-2,3-dihydro-6-methyl-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]- (CA INDEX NAME)

L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN


(Continued)




RN 491864-42-7 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 2,3-dihydro-6-methyl-1-[2-methyl-4-(trifluoromethoxy)phenyl]-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]- (CA INDEX NAME)




RN 491864-46-1 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]- (CA INDEX NAME)



RN 491865-57-7 CAPLUS
 CN 1H-Pyrrolo[2,3-b]pyridine,
 1-[2,4-bis(trifluoromethyl)phenyl]-2,3-dihydro-
 6-methyl-4-[3-(4-morpholinyl)-1H-pyrazol-1-yl]- (CA INDEX NAME)



RN 491865-58-8 CAPLUS
 CN 1H-Pyrrolo[2,3-b]pyridine,
 1-[2,4-bis(trifluoromethyl)phenyl]-2,3-dihydro-
 6-methyl-4-[3-(2-pyridinyl)-1H-pyrazol-1-yl]- (CA INDEX NAME)






RN 491865-59-9 CAPLUS
 CN 1H-Pyrrolo[2,3-b]pyridine, 4-[1,3'-bi-1H-pyrazol-1'-yl]-1-[2,4-bis(trifluoromethyl)phenyl]-2,3-dihydro-6-methyl- (CA INDEX NAME)


ACCESSION NUMBER: 2006:1093785 CAPLUS
 DOCUMENT NUMBER: 145:438617
 TITLE: Process for preparation of heterocyclylpyrrolopyridines from halopyrrolopyridines using copper catalysts.
 INVENTOR(S): Bacchi, Sergio; Delpogetto, Monica; Gueffi, Simone; Perboni, Alcide; Ribecai, Arianna; Stabile, Paolo; Tamplieri, Maria
 PATENT ASSIGNEE(S): SB Pharmco Puerto Rico Inc, USA; Neurocrine Biosciences Inc
 SOURCE: PCT Int. Appl., 37pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006108693	A2	20061019	WO 2006-EP3531	20060406
WO 2006108693	A3	20070705		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MM, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
AU 2006233740	A1	20061019	AU 2006-213740	20060406
CA 2604384	A1	20061019	CA 2006-2604384	20060406
EP 1874771	A2	20080109	EP 2006-724393	20060406
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
IN 2007DN07690	A	20071109	IN 2007-DN7690	20071008
KR 2008002937	A	20080104	KR 2007-725907	20071107
			GB 2005-7198	20050408
PRIORITY APPLN. INFO.: WO 2006-EP3531 W 20060406				

OTHER SOURCE(S): MARPAT 145:438617
 GI




AB Title compds. [I; R = (substituted) aryl, heteroaryl; R1 = H, cycloalkyl, alkyl, alkoxy, thioalkyl, alkenyl, alkynyl, haloalkyl, haloalkoxy, halo, amino, cyano; D = CR8R9, CR8; G = CR10R11, CR10; R8-R11 = H, cycloalkyl, alkyl, alkenyl, alkynyl, amino, cyano; dotted line = optional double bond; Z = (substituted) heterocyclyl; W = (substituted) carbocyclyl in which 1 atom is replaced by CO, SOm, or 1-4 C atoms may be replaced by O, N, imino, CO, SOm, CO; m = 0-2], were prepared by treatment of (II; X = halo; R, R1 as above) with a reactive derivative of WZ (variables as above) catalyzed by Cu. Thus, CuI and trans-N,N'-dimethyl-1,2-diaminocyclohexane were stirred together in DMF for 2-12 h; K2CO3, 1-(1H-pyrazol-3-yl)-2-imidazolidinone (preparation given), and 3-bromo-6-methyl-1-[2-methyl-4-(methoxy)phenyl]-2,3-dihydropyrrolo[2,3-b]pyridine (preparation given) in DMF were added followed by heating at 125° for 36-42 h to give 70% 1-[1-[1-(4-methoxy-2-methylphenyl)-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]imidazolidin-2-one. IT 491864-40-5P 491864-46-1P 786701-13-1P, 1-[1-[1-(4-methoxy-2-methylphenyl)-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]imidazolidin-2-one 786701-15-3P, 1-[1-[1-(4-methoxy-2-methylphenyl)-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-3-methylimidazolidin-2-one 786701-17-5P, 1-[1-[1-(2,4-dichlorophenyl)-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]imidazolidin-2-one 786701-22-2P 786701-25-5P 786701-27-7P 786701-29-9P, 1-[1-[6-methyl-1-[2-methyl-4-((trifluoromethyl)oxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]imidazolidin-2-one 786701-62-0P 786701-66-4P 786701-69-7P 786701-72-2P 786701-75-5P 786701-77-7P 786701-79-9P 786701-80-2P 786701-83-5P 912850-56-7P RL: IMP (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation) (preparation of heterocyclylpyrrolopyridines from halopyrrolopyridines using copper catalysts) RN 491864-40-5 CAPLUS CN Benzonitrile, 4-[2,3-dihydro-6-methyl-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]-1H-pyrrolo[2,3-b]pyridin-1-yl]-3-methyl- (CA INDEX NAME)




L4 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 491864-46-1 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]- (CA INDEX NAME)




RN 786701-13-1 CAPLUS
CN 2-Imidazolidinone, 1-[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 786701-15-3 CAPLUS
CN 2-Imidazolidinone, 1-[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-3-methyl- (CA INDEX NAME)

L4 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 786701-17-5 CAPLUS
CN 2-Imidazolidinone, 1-[1-[1-(2,4-dichlorophenyl)-2,3-dihydro-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 786701-22-2 CAPLUS
CN 2-Imidazolidinone, 1-acetyl-3-[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (CA INDEX NAME)

L4 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 786701-25-5 CAPLUS
CN 2-Imidazolidinone, 1-[1-[1-(4-ethoxy-2-methylphenyl)-2,3-dihydro-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 786701-27-7 CAPLUS
CN 2-Imidazolidinone, 1-[1-[2,3-dihydro-6-methyl-1-[2-methyl-4-(1-methylethoxy)phenyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (CA INDEX NAME)

L4 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 786701-29-9 CAPLUS
CN 2-Imidazolidinone, 1-[1-[2,3-dihydro-6-methyl-1-[2-methyl-4-(trifluoromethoxy)phenyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 786701-62-0 CAPLUS
CN 2-Imidazolidinone, 1-[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-5-methyl-1H-pyrazol-3-yl]- (CA INDEX NAME)

L4 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 786701-66-4 CAPLUS
CN 2-Pyrrolidinone, 1-[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 786701-69-7 CAPLUS
CN 2(1H)-Pyrimidinone, 1-[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]tetrahydro- (CA INDEX NAME)

L4 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 786701-72-2 CAPLUS
CN 2-Oxazolidinone, 3-[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 786701-75-5 CAPLUS
CN 1,2,5-Thiadiazolidine-2-carboxylic acid, 5-[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-, methyl ester, 1,1-dioxide (CA INDEX NAME)

L4 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 786701-77-7 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 4-[3-[(1,1-dioxido-1,2,5-thiadiazolidin-2-yl)-1H-pyrazol-1-yl]-2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl- (CA INDEX NAME)




RN 786701-79-9 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 4-[3-[(1,1-dioxido-2-isothiazolidinyl)-1H-pyrazol-1-yl]-2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl- (CA INDEX NAME)


L4 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 786701-80-2 CAPLUS
CN 2(1H)-Pyridinone, 1-[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-3-methyl- (CA INDEX NAME)



RN 786701-83-5 CAPLUS
CN 2H-Imidazol-2-one, 1-[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-1,3-dihydro- (CA INDEX NAME)




RN 912850-56-7 CAPLUS
CN 3-(2H)-Pyridazinone, 2-[1-(2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-3-yl]tetrahydro- (CA INDEX NAME)



ACCESSION NUMBER: 2004:927207 CAPLUS
DOCUMENT NUMBER: 141:395557
TITLE: Preparation of condensed heterocycles as CRF receptor antagonists for treatment of depression, anxiety, IBS, and IBD
INVENTOR(S): Andreotti, Daniele; Bernasconi, Giovanni; Castiglioni, Emiliano; Contini, Stefania; Di Fabio, Romano; Fazzolari, Elettra; Feriani, Aldo; Gentile, Gabriella; Mattioli, Mario; Mingardi, Anna; Sabbatini, Fabio; St.-Denis, Yves
PATENT ASSIGNEE(S): SB Pharmco Puerto Rico Inc., USA; Neurocrine Biosciences Inc.
SOURCE: PCT Int. Appl., 129 pp.
CODEN: FIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004094420	A1	20041104	WO 2004-1B1350	20040407
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004232551	A1	20041104	AU 2004-232551	20040407
CA 2521929	A1	20041104	CA 2004-2521929	20040407
EP 1611133	A1	20050104	EP 2004-726237	20040407
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004009117	A	20060328	BR 2004-9117	20040407
CN 1805958	A	20060719	CN 2004-80016189	20040407
JP 2006522799	T	20061005	JP 2006-506558	20040407
IN 2005DN04455	A	20070831	IN 2005-DN4455	20051003
MX 2005PA10874	A	20060321	MX 2005-PA10874	20051010
NO 2005005238	A	20060109	NO 2005-5238	20051108
US 2007004708	A1	20070104	US 2006-552493	20060921
PRIORITY APPLN. INFO.:				
			GB 2003-8208	A 20030409
			US 2003-485322P	P 20030707
			WO 2004-1B1350	W 20040407

OTHER SOURCE(S): MARPAT 141:395557
G1




AB Title [(pyrrolo[2,3-b]pyridinyl)pyrazolyl]imidazolidinone and related compds. I [wherein D = CR8R9, CR8; G = CR10R11, CR10; W = (un)substituted carboxycyl, heterocycyl; X = C, N; Y = H, CR7; Z = (un)substituted heterocycyl, Ph; R = (un)substituted (hetero)aryl; R1 = H, (cyclo)alkyl, (halo)alkoxy, alkylthio, alkenyl, alkynyl, halo(alkyl), halo, NR3R4, CN; R3, R4 = independently H, alkyl; R7 = H, (halo)alkyl, halo; R8-R11 = independently H, (cyclo)alkyl, alkenyl, alkynyl, NR3R4, CN; and stereoisomers, prodrugs and pharmaceutically acceptable salts, or solvates thereof] were prepared as corticotropin-releasing factor (CRF) antagonists.

For example, 4-iodo-6-methyl-1-[2-methyl-4-(methoxyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine was coupled with 1-[(1H-pyrazol-3-yl)imidazolidin-2-one (preparation of reactants given) in the presence of CuI, K2CO3, dodecane, and trans-cyclohexanediamine in anh. NMP to afford II (53%). In binding assays using recombinant human CRF1 and CRF2 receptors expressed in CHO cell membranes, compds. of the invention showed affinity for CRF receptors with Ki values of <10 μM. Thus, I and their pharmaceutical compns. are useful for the treatment of depression, anxiety, IBS, and IBD (no data).

IT 786701-13-1P, 1-[1-[1-(4-Methoxy-2-methylphenyl)-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]imidazolidin-2-one R1: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic Preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (CRF antagonist; preparation of [(pyrrolopyridinyl)pyrazolyl]imidazolidinone and related compds. as CRF receptor antagonists for treatment of depression, anxiety, IBS, and IBD)

RN 786701-13-1 CAPLUS
CN 2-Imidazolidinone, 1-[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (CA INDEX NAME)



IT 786701-15-3P, 1-[1-[1-(4-Methoxy-2-methylphenyl)-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-3-methylimidazolidin-2-one 786701-17-5P, 1-[1-[1-(2,4-Dichlorophenyl)-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]imidazolidin-2-one 786701-19-7P, 1-[1-[1-[2,4-Bis(trifluoromethyl)phenyl]-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-2-imidazolidinone 786701-20-0P, 1-[1-[1-(4-Hydroxy-2-methylphenyl)-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-2-imidazolidinone 786701-22-2P, 1-Acetyl-3-[1-[6-methyl-1-[2-methyl-4-(methoxyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-2-imidazolidinone 786701-25-5P, 1-[1-[1-[4-(Ethoxyloxy)-2-methylphenyl]-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-2-imidazolidinone 786701-27-7P, 1-[1-[6-Methyl-1-[2-methyl-4-[(1-methylethoxy)oxy]phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-2-imidazolidinone 786701-29-9P, 1-[1-[6-Methyl-1-[2-methyl-4-[(trifluoromethyl)oxy]phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-2-imidazolidinone 786701-31-3P, 3-Methyl-4-[6-methyl-4-[3-(2-oxo-1-imidazolidinyl)-1H-pyrazol-1-yl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]benzonitrile 786701-34-6P, 1-[1-[6-Methyl-1-[2-methyl-4-(1H-pyrazol-1-yl)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-2-imidazolidinone 786701-35-7P, 4-[6-Methyl-4-[3-(2-oxo-1-imidazolidinyl)-1H-pyrazol-1-yl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-1-yl]-3-(trifluoromethyl)benzonitrile 786701-37-9P, 1-[1-[1-[2-(difluoromethyl)-4-(methoxyloxy)phenyl]-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-2-imidazolidinone 786701-40-4P, 4-[6-Methyl-4-[3-(2-oxo-1-imidazolidinyl)-1H-pyrazol-1-yl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-1-yl]-3-(trifluoromethyl)benzonitrile 786701-43-7P, 3-Ethyl-4-[6-methyl-4-[3-(2-oxo-1-imidazolidinyl)-1H-pyrazol-1-yl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-1-yl]benzonitrile 786701-44-8P, 1-[1-[6-Methyl-1-[2-methyl-4-(1H-pyrazol-1-yl)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-2-imidazolidinone 786701-46-0P, 1-[1-[6-Methyl-1-[6-methyl-1,3-benzodioxol-5-yl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-2-imidazolidinone 786701-49-3P, 1-[1-[6-methyl-1-[2,4,6-

L4 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 tris(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-2-imidazolidinone 786701-57-3P,
 1-[1-[2,6-Dimethyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-2-imidazolidinone 786701-62-0P, 1-[5-Methyl-1-[6-methyl-1-[2-methyl-4-

(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-2-imidazolidinone 786701-64-2P, 1-[1-[1-[4-

[(difluoromethyl)oxy]-2-methylphenyl]-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-2-imidazolidinone 786701-66-4P, 1-[1-[1-(4-Methoxy-2-methylphenyl)-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]pyrrolidin-2-one 786701-69-7P, 1-[1-[1-(4-Methoxy-2-methylphenyl)-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]tetrahydropyrimidin-2(1H)-one 786701-72-2P, 3-[1-[6-Methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-1,3-oxazolidin-2-one 786701-75-5P 786701-77-7P, 4-[3-[1,1-Dioxido-1,2,5-thiadiazolidin-2-yl]-1H-pyrazol-1-yl]-6-methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine 786701-79-9P, 4-[3-[1,1-Dioxido-2-isothiazolidinyl]-1H-pyrazol-1-yl]-6-methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine 786701-80-2P, 3-Methyl-1-[1-[6-methyl-1-[2-methyl-4-

(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-2(1H)-pyridinone 786701-81-3P, 2-[1-[6-Methyl-1-[2-methyl-4-

(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-3(2H)-pyridazinone 786701-83-5P, 1-[1-[6-Methyl-1-[2-methyl-


4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-1,3-dihydro-2H-imidazol-2-one

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(CRF antagonist; prepn. of (pyrrolopyridinyl)pyrazolyl)imidazolidinone a and related compds. as CRF receptor antagonists for treatment of depression, anxiety, IBS, and IBD)

RN 786701-15-3 CAPLUS
 CN 2-Imidazolidinone,
 1-[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-3-methyl- (CA INDEX NAME)

L4 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 786701-17-5 CAPLUS
 CN 2-Imidazolidinone, 1-[1-[1-(2,4-dichlorophenyl)-2,3-dihydro-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 786701-19-7 CAPLUS
 CN 2-Imidazolidinone,
 1-[1-[1-(2,4-bis(trifluoromethyl)phenyl)-2,3-dihydro-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (CA INDEX NAME)

L4 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 786701-20-0 CAPLUS
 CN 2-Imidazolidinone,
 1-[1-[2,3-dihydro-1-(4-hydroxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 786701-22-2 CAPLUS
 CN 2-Imidazolidinone,
 1-acetyl-3-[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (CA INDEX NAME)


L4 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 786701-25-5 CAPLUS
 CN 2-Imidazolidinone,
 1-[1-[1-(4-ethoxy-2-methylphenyl)-2,3-dihydro-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 786701-27-7 CAPLUS
 CN 2-Imidazolidinone, 1-[1-[2,3-dihydro-6-methyl-1-[2-methyl-4-(1-methylethoxy)phenyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 786701-29-9 CAPLUS
CN 2-Imidazolidinone, 1-[1-[2,3-dihydro-6-methyl-1-(2-methyl-4-(trifluoromethoxy)phenyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 786701-31-3 CAPLUS
CN Benzonitrile, 4-[2,3-dihydro-6-methyl-4-{3-(2-oxo-1-imidazolidinyl)-1H-pyrazol-1-yl}-1H-pyrrolo[2,3-b]pyridin-1-yl]-3-methyl- (CA INDEX NAME)




RN 786701-34-6 CAPLUS
CN 2-Imidazolidinone, 1-[1-[2,3-dihydro-6-methyl-1-(2-methyl-4-(1H-pyrazol-1-yl)phenyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 786701-35-7 CAPLUS
CN Benzonitrile, 4-[2,3-dihydro-6-methyl-4-{3-(2-oxo-1-imidazolidinyl)-1H-pyrazol-1-yl}-1H-pyrrolo[2,3-b]pyridin-1-yl]-3-(trifluoromethyl)- (CA INDEX NAME)




RN 786701-37-9 CAPLUS
CN 2-Imidazolidinone, 1-[1-[2-(difluoromethyl)-4-methoxyphenyl]-2,3-dihydro-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 786701-40-4 CAPLUS
CN Benzonitrile, 4-[2,3-dihydro-6-methyl-4-{3-(2-oxo-1-imidazolidinyl)-1H-pyrazol-1-yl}-1H-pyrrolo[2,3-b]pyridin-1-yl]-3-(trifluoromethoxy)- (CA INDEX NAME)




RN 786701-43-7 CAPLUS
CN Benzonitrile, 4-[2,3-dihydro-6-methyl-4-{3-(2-oxo-1-imidazolidinyl)-1H-pyrazol-1-yl}-1H-pyrrolo[2,3-b]pyridin-1-yl]-3-ethyl- (CA INDEX NAME)




RN 786701-44-8 CAPLUS
CN 2-Imidazolidinone, 1-[1-[2,3-dihydro-1-(2-methoxy-4-(1H-pyrazol-1-yl)phenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 786701-46-0 CAPLUS
CN 2-Imidazolidinone,
1-[1-[2,3-dihydro-6-methyl-1-(6-methyl-1,3-benzodioxol-5-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 786701-49-3 CAPLUS
CN 2-Imidazolidinone, 1-[1-[2,3-dihydro-6-methyl-1-(2,4,6-trimethoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 786701-57-3 CAPLUS
CN 2-Imidazolidinone, 1-[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-2,6-dimethyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 786701-62-0 CAPLUS
CN 2-Imidazolidinone,
1-[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-5-methyl-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 786701-64-2 CAPLUS
CN 2-Imidazolidinone, 1-[1-[2,3-dihydro-1-(4-(difluoromethoxy)-2-methylphenyl)-2,3-dihydro-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 786701-66-4 CAPLUS
CN 2-Pyrrolidinone, 1-[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 786701-69-7 CAPLUS
CN 2(1H)-Pyrimidinone, 1-[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]tetrahydro- (CA INDEX NAME)




RN 786701-72-2 CAPLUS
CN 2-Oxazolidinone, 3-[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 786701-75-5 CAPLUS
CN 1,2,5-Thiadiazolidine-2-carboxylic acid,
5-[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-methyl ester, 1,1-dioxide (CA INDEX NAME)




RN 786701-77-7 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine,
4-[3-(1,1-dioxido-1,2,5-thiadiazolidin-2-yl)-1H-pyrazol-1-yl]-2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl- (CA INDEX NAME)




RN 786701-81-3 CAPLUS
CN 3(2H)-Pyridazinone, 2-[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 786701-83-5 CAPLUS
CN 2H-Imidazol-2-one,
1-[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-1,3-dihydro- (CA INDEX NAME)



RN 786701-79-9 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 4-[3-(1,1-dioxido-2-isothiazolidinyl)-1H-pyrazol-1-yl]-2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl- (CA INDEX NAME)



RN 786701-80-2 CAPLUS
CN 2(1H)-Pyridinone,
1-[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-3-methyl- (CA INDEX NAME)




IT 786700-23-0P, N-[1-[6-Methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]acetamide
786700-24-1P, 1-[6-Methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-amine
786700-25-2P 786700-26-3P, 2-[1-[6-Methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]aminoethanol 786700-27-4P, 3-[1-[6-Methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]amino]-1-propanesulfonic acid 786700-28-5P, Phenyl [1-[6-methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]carbamate 786700-29-6P,
1-(2,2-Diethoxyethyl)-3-[1-[6-methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]urea
786700-34-3P, 1-Acetyl-3-[1-[1-(4-hydroxy-2-methylphenyl)-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-2-imidazolidinone 786700-35-4P, 1-Acetyl-3-[1-[1-(4-(ethyloxy)-2-methylphenyl)-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-2-imidazolidinone 786700-36-5P,
1-Acetyl-3-[1-[6-methyl-1-[2-methyl-4-(1-methylethyl)oxy]phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-2-imidazolidinone 786700-37-6P, 1-(1-Methylethyl)-3-[1-[6-methyl-1-[2-methyl-4-(1-methylethyl)oxy]phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-2-imidazolidinone 786700-48-9P,
1-[1-[6-Methyl-1-[2-methyl-4-(trifluoromethyl)oxy]phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-3-[1-[4-(methyloxy)phenyl]methyl]-2-imidazolidinone 786700-51-4P,
1-Methyl-4-[6-methyl-4-[3-[3-[4-(methyloxy)phenyl]methyl]-2-oxo-1-imidazolidinyl]-1H-pyrazol-1-yl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-1-yl]benzonitrile 786700-54-7P, 1-[1-[6-Methyl-1-[2-methyl-4-(1H-pyrazol-1-yl)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-3-[1-[4-(methyloxy)phenyl]methyl]-2-imidazolidinone 786700-57-0P, 4-[6-Methyl-4-[3-[3-[4-(methyloxy)phenyl]methyl]-2-oxo-1-imidazolidinyl]-1H-pyrazol-1-yl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-1-yl]-3-(trifluoromethyl)benzonitrile 786700-60-5P,
1-[1-[1-[2-(Difluoromethyl)-4-(methyloxy)phenyl]-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-3-[1-[4-

L4 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
(methyloxy)phenyl)methyl]-2-imidazolidinone 786700-64-9P.


4-[6-Methyl-4-{3-[3-[(4-(methyloxy)phenyl)methyl]-2-oxo-1-imidazolidinyl]-1H-pyrazol-1-yl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-1-yl]-3-[(trifluoromethyl)oxy]benzonitrile 786700-67-2P,
3-Ethyl-4-[6-methyl-4-{3-[3-[(4-(methyloxy)phenyl)methyl]-2-oxo-1-imidazolidinyl]-1H-pyrazol-1-yl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-1-yl]benzonitrile 786700-71-8P, 1-[1-[6-Methyl-1-[2-(methyloxy)-4-(1H-pyrazol-1-yl)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-3-[(4-(methyloxy)phenyl)methyl]-2-imidazolidinone 786700-74-1P, 1-[1-[6-Methyl-1-(6-methyl-1,3-benzodioxol-5-yl)-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-3-[(4-(methyloxy)phenyl)methyl]-2-imidazolidinone 786700-77-4P,
1-[[4-(Methyloxy)phenyl)methyl]-3-[1-[6-methyl-1-[2,4,6-tris(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-2-imidazolidinone 786700-81-0P,
1-[1-[2,4-Bis(trifluoromethyl)phenyl]-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-3-[(4-(methyloxy)phenyl)methyl]-2-imidazolidinone 786701-03-9P,
1-[1-[2,6-Dimethyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-3-[(4-(methyloxy)phenyl)methyl]-2-imidazolidinone 786701-09-5P,
5-Methyl-1-[6-methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-amine 786701-11-9P,
1-Acetyl-3-[1-[1-[4-[(difluoromethyl)oxy]-2-methylphenyl]-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-2-imidazolidinone
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of [(pyrrolopyridinyl)pyrazolyl]imidazolidinones and related compds. as CRF receptor antagonists for treatment of depression, anxiety, IBS, and IBD)

RN 786700-23-0 CAPLUS
CN Acetamide, N-[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 786700-24-1 CAPLUS
CN 1H-Pyrazol-3-amine, 1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]- (CA INDEX NAME)


L4 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 786700-25-2 CAPLUS
CN Glycine, N-[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-, ethyl ester (CA INDEX NAME)




RN 786700-26-3 CAPLUS
CN Ethanol, 2-[[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]amino]- (CA INDEX NAME)




RN 786700-27-4 CAPLUS
CN 1-Propanesulfonic acid, 3-[[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]amino]- (CA INDEX NAME)


L4 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
NAME)



RN 786700-28-5 CAPLUS
CN Carbanic acid, 1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl-, phenyl ester (9CI) (CA INDEX NAME)




RN 786700-29-6 CAPLUS
CN Urea, N-(2,2-diethoxyethyl)-N'-[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (CA INDEX NAME)




L4 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 786700-34-3 CAPLUS
CN 2-Imidazolidinone, 1-acetyl-3-[1-[2,3-dihydro-1-(4-hydroxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 786700-35-4 CAPLUS
CN 2-Imidazolidinone, 1-acetyl-3-[1-[1-(4-ethoxy-2-methylphenyl)-2,3-dihydro-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (CA INDEX NAME)



RN 786700-36-5 CAPLUS
CN 2-Imidazolidinone, 1-acetyl-3-[1-[2,3-dihydro-6-methyl-1-[2-methyl-4-(1-methylethoxy)phenyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 786700-37-6 CAPLUS
CN 2-Imidazolidinone, 1-[1-(2,3-dihydro-6-methyl-1-(2-methyl-4-(1-methylethoxy)phenyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-3-yl]-3-(1-methylethyl)- (CA INDEX NAME)



RN 786700-48-9 CAPLUS
CN 2-Imidazolidinone, 1-[1-(2,3-dihydro-6-methyl-1-(2-methyl-4-(trifluoromethoxy)phenyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-3-yl]-3-[(4-methoxyphenyl)methyl]- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A

RN 786700-51-4 CAPLUS
CN Benzonitrile, 4-[2,3-dihydro-4-[3-[3-[(4-methoxyphenyl)methyl]-2-oxo-1-imidazolidinyl]-1H-pyrazol-1-yl]-6-methyl-1H-pyrrolo[2,3-b]pyridin-1-yl]-3-methyl- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A

RN 786700-54-7 CAPLUS
CN 2-Imidazolidinone, 1-[1-(2,3-dihydro-6-methyl-1-(2-methyl-4-(1H-pyrazol-1-yl)phenyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-3-yl]-3-[(4-methoxyphenyl)methyl]- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A

RN 786700-57-0 CAPLUS
CN Benzonitrile, 4-[2,3-dihydro-4-[3-[3-[(4-methoxyphenyl)methyl]-2-oxo-1-imidazolidinyl]-1H-pyrazol-1-yl]-6-methyl-1H-pyrrolo[2,3-b]pyridin-1-yl]-3-(trifluoromethyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 786700-60-5 CAPLUS
CN 2-Imidazolidinone, 1-([1-([2-(difluoromethyl)-4-methoxyphenyl]-2,3-dihydro-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-3-yl]-3-[(4-methoxyphenyl)methyl])- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 786700-64-9 CAPLUS
CN Benzonitrile, 4-[2,3-dihydro-4-[3-[3-[(4-methoxyphenyl)methyl]-2-oxo-1-imidazolidinyl]-1H-pyrazol-1-yl]-6-methyl-1H-pyrrolo[2,3-b]pyridin-1-yl]-3-[(4-methoxyphenyl)methyl])- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 786700-67-2 CAPLUS
CN Benzonitrile, 4-[2,3-dihydro-4-[3-[3-[(4-methoxyphenyl)methyl]-2-oxo-1-imidazolidinyl]-1H-pyrazol-1-yl]-6-methyl-1H-pyrrolo[2,3-b]pyridin-1-yl]-3-ethyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 786700-71-8 CAPLUS
CN 2-Imidazolidinone, 1-([1-([2,3-dihydro-1-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-3-[(4-methoxyphenyl)methyl])- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 786700-74-1 CAPLUS
 CN 2-Imidazolidinone,
 1-([1-(2,3-dihydro-6-methyl-1-(6-methyl-1,3-benzodioxol-5-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-3-yl]-3-((4-methoxyphenyl)methyl))- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 786700-77-4 CAPLUS
 CN 2-Imidazolidinone, 1-([1-(2,3-dihydro-6-methyl-1-(2,4,6-trimethoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-3-yl]-3-((4-methoxyphenyl)methyl))- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 786700-81-0 CAPLUS
 CN 2-Imidazolidinone,
 1-([1-(2,4-bis(trifluoromethyl)phenyl)-2,3-dihydro-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-3-yl]-3-((4-methoxyphenyl)methyl))- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 786701-03-9 CAPLUS
 CN 2-Imidazolidinone, 1-([1-(2,3-dihydro-1-(4-methoxy-2-methylphenyl)-2,6-dimethyl-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-3-yl]-3-((4-methoxyphenyl)methyl))- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 786701-09-5 CAPLUS
CN 1H-Pyrazol-3-amine, 1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-5-methyl- (CA INDEX NAME)






RN 786701-11-9 CAPLUS
CN 2-Indazolidinone, 1-acetyl-3-[1-[(4-(difluoromethoxy)-2-methylphenyl)-2,3-dihydro-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (CA INDEX NAME)

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:610082 CAPLUS
DOCUMENT NUMBER: 141:157105
TITLE: Preparation of heteroaryl-substituted pyrrolo[2,3-b]pyridine derivatives as CRF receptor antagonists
INVENTOR(S): Castiglioni, Emiliano; Di Fabio, Romano; Feriani, Aldo; Micheli, Fabrizio; Sabbatini, Fabio; St-Denis, Yves
PATENT ASSIGNEE(S): SB Pharmco Puerto Rico Inc., USA; Neurocrine Biosciences Inc.; Glaxo Group Limited
SOURCE: PCT Int. Appl., 72 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004062665	A1	20040729	WO 2004-EP409	20040114
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ				
EP 1583531	B1	20051012	EP 2004-701955	20040114
EP 1583531	B1	20070418		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006515334	T	20060525	JP 2006-500001	20040114
AT 359782	T	20070515	AT 2004-701955	20040114
ES 2285409	T3	20071116	ES 2004-4701955	20040114
US 2007066640	A1	20070322	US 2006-542196	20060303
PRIORITY APPLN. INFO.:				P 20030116
				WO 2004-EP409 W 20040114


OTHER SOURCE(S): MARPAT 141:157105
GI



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT


L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

AB Pyrrolo[2,3-b]pyridines of formula I [R = aryl, heteroaryl; R1 = H, cycloalkyl, alkyl, alkoxy, CN, etc.; NR2R3 = (substituted) aromatic heterocycle; R4 = H, alkyl, halo, haloalkyl] are described, including stereoisomers, prodrugs and pharmaceutically acceptable salts or solvates thereof, processes for their preparation, pharmaceutical compns. containing them and their use in the treatment of conditions mediated by corticotropin-releasing factor (CRF). Thus, II was prepared in several steps.
IT 727992-87-2P 727992-88-3P 727992-89-4P 727992-90-7P 727992-91-8P 727992-92-9P 727992-93-0P 727992-94-1P 727992-95-2P 727992-96-3P 727992-97-4P 727992-98-5P 727992-99-6P 727993-00-2P 727993-01-3P 727993-02-4P 727993-03-5P 727993-04-6P 727993-05-7P 727993-06-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heteroaryl pyrrolopyridine derivs. as CRF receptor antagonists)
RN 727992-87-2 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 2,3-dihydro-1-(6-methoxy-2-(trifluoromethyl)-3-pyridinyl)-6-methyl-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]- (CA INDEX NAME)




RN 727992-88-3 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 2,3-dihydro-1-(6-methoxy-2-methyl-3-pyridinyl)-6-methyl-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]- (CA INDEX NAME)


L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 727992-89-4 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 1-(2,6-dimethoxy-3-pyridinyl)-2,3-dihydro-6-methyl-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]- (CA INDEX NAME)




RN 727992-90-7 CAPLUS
CN 2-Pyridinamine, 5-[2,3-dihydro-6-methyl-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]-1H-pyrrolo[2,3-b]pyridin-1-yl]-N,N,4-trimethyl- (CA INDEX NAME)




RN 727992-91-8 CAPLUS


L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 727992-94-1 CAPLUS
CN Benzonitrile, 3-chloro-4-[2,3-dihydro-6-methyl-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]-1H-pyrrolo[2,3-b]pyridin-1-yl]-3-ethyl- (CA INDEX NAME)




RN 727992-95-2 CAPLUS
CN Benzonitrile, 3-chloro-4-[2,3-dihydro-6-methyl-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]-1H-pyrrolo[2,3-b]pyridin-1-yl]-3-ethyl- (CA INDEX NAME)



L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
CN 1H-Pyrrolo[2,3-b]pyridine, 1-[2-(difluoromethyl)-4-methoxyphenyl]-2,3-dihydro-6-methyl-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]- (CA INDEX NAME)




RN 727992-92-9 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 1-(2-chloro-4-methoxyphenyl)-2,3-dihydro-6-methyl-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]- (CA INDEX NAME)




RN 727992-93-0 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 1-(2,4-dimethoxyphenyl)-2,3-dihydro-6-methyl-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]- (CA INDEX NAME)

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 727992-96-3 CAPLUS
CN Benzonitrile, 3-chloro-4-[2,3-dihydro-6-methyl-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]-1H-pyrrolo[2,3-b]pyridin-1-yl]-3-ethyl- (CA INDEX NAME)




RN 727992-97-4 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 1-(4-fluoro-2-methylphenyl)-2,3-dihydro-6-methyl-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]- (CA INDEX NAME)




RN 727992-98-5 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 1-(2-methyl-4-[2-methyl-1-[2-methyl-1-[2-methyl-1-yl]phenyl]-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]- (CA INDEX NAME)

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 727992-99-6 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 2,3-dihydro-6-methyl-1-[(4-nitro-2-(trifluoromethyl)phenyl)-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]]- (CA INDEX NAME)




RN 727993-00-2 CAPLUS
CN Benzonitrile, 4-[(4-[(1,3'-bi-1H-pyrazol)-1'-yl]-2,3-dihydro-6-methyl-1H-pyrrolo[2,3-b]pyridin-1-yl)-3-methyl]- (CA INDEX NAME)

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 727993-01-3 CAPLUS
CN Benzonitrile, 4-[(4-[(1,3'-bi-1H-pyrazol)-1'-yl]-2,3-dihydro-6-methyl-1H-pyrrolo[2,3-b]pyridin-1-yl)-3-(trifluoromethyl)]- (CA INDEX NAME)




RN 727993-02-4 CAPLUS
CN Benzonitrile, 4-[(4-[(1,3'-bi-1H-pyrazol)-1'-yl]-2,3-dihydro-6-methyl-1H-pyrrolo[2,3-b]pyridin-1-yl)-3-chloro]- (CA INDEX NAME)

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 727993-03-5 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 4-[(1,3'-bi-1H-pyrazol)-1'-yl]-2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl- (CA INDEX NAME)




RN 727993-04-6 CAPLUS
CN Benzonitrile, 4-[(2,3-dihydro-6-methyl-4-[3-(2-pyridinyl)-1H-pyrazol-1-yl]-1H-pyrrolo[2,3-b]pyridin-1-yl)-3-methyl]- (CA INDEX NAME)


L4 . ANSWER 4 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 727993-05-7 CAPLUS
CN Benzonitrile, 3-chloro-4-[2,3-dihydro-6-methyl-4-[3-(2-pyridinyl)-1H-pyrazol-1-yl]-1H-pyrrolo[2,3-b]pyridin-1-yl]- (CA INDEX NAME)



RN 727993-06-8 CAPLUS
CN Benzonitrile, 4-[2,3-dihydro-6-methyl-4-[3-(2-pyridinyl)-1H-pyrazol-1-yl]-1H-pyrrolo[2,3-b]pyridin-1-yl)-3-(trifluoromethyl)- (CA INDEX NAME)



IT 491865-06-6P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of heteroaryl pyrrolopyridine derivs. as CRF receptor
 antagonists)
 RN 491865-06-6 CAPLUS
 CN 1H-Pyrrolo[2,3-b]pyridine, 2,3-dihydro-6-methyl-4-[3-(2-thiazolyl)-1H-
 pyrazol-1-yl]- (CA INDEX NAME)



ACCESSION NUMBER: 2003:76778 CAPLUS
 DOCUMENT NUMBER: 138:137173
 TITLE: Preparation of pyrazolyl- pyrrolo[2,3-b]pyridines and
 tetrahydro[1,8]naphthyridines as CRF receptor
 antagonists
 INVENTOR(S): Di Fabio, Romano; Micheli, Fabrizio; St-denis, Yves
 PATENT ASSIGNEE(S): Glaxo Group Limited, UK
 SOURCE: PCT Int. Appl., 35 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003008412	A2	20030110	WO 2002-EP7865	20020715
WO 2003008412	A3	20030501		
M: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RM: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
GB 2378702	A	20030219	GB 2002-16041	20020711
CA 2451530	A1	20030110	CA 2002-2451530	20020715
AU 2002229899	A1	20030103	AU 2002-128899	20020715
EP 1425280	A2	20040609	EP 2002-764696	20020715
EP 1425280	B1	20060830		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002011171	A	20040810	BR 2002-11171	20020715
CN 1525972	A	20040901	CN 2002-813866	20020715
HU 2004000465	A2	20050128	HU 2004-465	20020715
JP 2005514328	T	20050519	JP 2003-513971	20020715
NZ 530043	A	20060331	NZ 2002-530043	20020715
EP 1695974	A1	20060830	EP 2006-76176	20020715
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
AT 338042	T	20060915	AT 2002-764696	20020715
ES 2271327	T3	20070416	ES 2002-2764696	20020715
RU 2310655	C2	20071120	RU 2004-104349	20020715
IN 20030802137	A	20070302	IN 2003-DN2137	20031209
ZA 2003009708	A	20050121	ZA 2003-9708	20031215
US 2004171607	A1	20040902	US 2004-483792	20040114
US 7253284	B2	20070807		
NO 2004000206	A	20040316	NO 2004-206	20040116
MX 2004PA00494	A	20040504	MX 2004-PA494	20040116
HK 1065535	A1	20070309	HK 2004-109443	20041130
US 2007219232	A1	20070920	US 2007-749433	20070516
PRIORITY APPLN. INFO.:				GB 2001-17396 A 20010717
				EP 2002-764696 A3 20020715
				WO 2002-EP7865 W 20020715

OTHER SOURCE(S): MARPAT 138:137173
 GI


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Pyrazolyl- pyrrolo[2,3-b]pyridines and tetrahydro[1,8]naphthyridines (I; wherein R = (substituted) aryl, heteroaryl; R1 = H, (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, halo(C1-C6)alkyl, halo(C1-C6)alkoxy, halogen, amino, or cyano; R2 = H, (C3-C7)cycloalkyl; R3 = (C3-C7)cycloalkyl; or R2 and R3 together with N form a (substituted) 5-14 membered heterocycle; R4 = H, (C1-C6)alkyl, halo, halo(C1-C6)alkyl; X =


C, N; n = 1 or 2) were prepared For example, compound (II) was prepared by the provided method. The prepared compds. are useful in the treatment of conditions mediated by corticotropin-releasing factor (CRF) (no data).

IT 491864-38-1P 491864-40-5P 491864-41-6P
 491864-42-7P 491864-46-1P 491865-57-7P
 491865-58-8P 491865-59-9P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of pyrazolyl- pyrrolo[2,3-b]pyridines and tetrahydro[1,8]naphthyridines as CRF receptor antagonists)
 RN 491864-38-1 CAPLUS
 CN 1H-Pyrrolo[2,3-b]pyridine,
 1-[2,4-bis(trifluoromethyl)phenyl]-2,3-dihydro-
 6-methyl-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]- (CA INDEX NAME)




RN 491864-40-5 CAPLUS
 CN Benzonitrile,
 4-[2,3-dihydro-6-methyl-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]-
 1H-pyrrolo[2,3-b]pyridin-1-yl]-3-methyl- (CA INDEX NAME)




RN 491864-41-6 CAPLUS
 CN Benzonitrile,
 4-[2,3-dihydro-6-methyl-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]-
 1H-pyrrolo[2,3-b]pyridin-1-yl]-3-(trifluoromethyl)- (CA INDEX NAME)




RN 491864-42-7 CAPLUS
 CN 1H-Pyrrolo[2,3-b]pyridine, 2,3-dihydro-6-methyl-1-[2-methyl-4-(trifluoromethoxy)phenyl]-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]- (CA INDEX NAME)




RN 491864-46-1 CAPLUS
 CN 1H-Pyrrolo[2,3-b]pyridine, 2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]- (CA INDEX NAME)




RN 491865-57-7 CAPLUS
 CN 1H-Pyrrolo[2,3-b]pyridine, 1-[2,4-bis(trifluoromethyl)phenyl]-2,3-dihydro-6-methyl-4-[3-(4-morpholinyl)-1H-pyrazol-1-yl]- (CA INDEX NAME)




RN 491865-58-8 CAPLUS
 CN 1H-Pyrrolo[2,3-b]pyridine, 1-[2,4-bis(trifluoromethyl)phenyl]-2,3-dihydro-6-methyl-4-[3-(2-pyridinyl)-1H-pyrazol-1-yl]- (CA INDEX NAME)



RN 491865-59-9 CAPLUS
 CN 1H-Pyrrolo[2,3-b]pyridine, 4-[1,3'-bi-1H-pyrazol]-1'-yl-1-[2,4-bis(trifluoromethyl)phenyl]-2,3-dihydro-6-methyl- (CA INDEX NAME)



IT 491865-06-6P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of pyrazolyl- pyrrolo[2,3-b]pyridines and tetrahydro[1,8]naphthyridines as CRF receptor antagonists)
 RN 491865-06-6 CAPLUS
 CN 1H-Pyrrolo[2,3-b]pyridine, 2,3-dihydro-6-methyl-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]- (CA INDEX NAME)



=> d his

(FILE 'HOME' ENTERED AT 18:24:28 ON 30 JAN 2008)

FILE 'REGISTRY' ENTERED AT 18:24:38 ON 30 JAN 2008

L1 STRUCTURE UPLOADED

L2 4 S L1

L3 86 S L1 FULL

FILE 'CAPLUS' ENTERED AT 18:25:17 ON 30 JAN 2008

L4 5 S L3 FULL

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

27.73

206.30

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-4.00

-4.00

STN INTERNATIONAL LOGOFF AT 18:26:06 ON 30 JAN 2008

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	1783	(514/300,546/113).CCLS.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2008/01/30 18:35
L2	774	I1 and bicyclic	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2008/01/30 18:36
L3	254	I2 and imidazol	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2008/01/30 18:38
L4	194	I3 and pyridin	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2008/01/30 18:39
L5	54	I4 and pyrrolo	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2008/01/30 18:39